Spotlight on molecular profiling: "Integromic" analysis of the NCI-60 cancer cell lines

Molecular Cancer Therapeutics

Volumn 5, Issue 11, 2006, Pages 2601-2605

  Weinstein, John N ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER CELL CULTURE; DATA BASE; DRUG ACTIVITY; HUMAN; HUMAN CELL; HYPOTHESIS; NOTE; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEOMICS; PUBLICATION;

CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION PROFILING; HUMANS; MODELS, BIOLOGICAL; PROTEOMICS;

EID: 33845226443     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0640     Document Type: Note

References (27)

1. Boyd MR, Paull KD. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev Res 1995;34:91-109.
2. Holbeck SL. Update on NCI in vitro drug screen utilities. Eur J Cancer 2004;40:785-93.
3. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006;6:813-23.
4. Weinstein JN. Integromic analysis of the NCI-60 cancer cell lines. Breast Dis 2004; 19:11-22.
5. Paull KD, Shoemaker RH, Hodes L, et al. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 1989;81:1088-92.
6. Weinstein JN, Kohn KW, Graver MR, et al. Neural computing in cancer drug development: predicting mechanism of action. Science 1992;258: 447-51.
7. van Osdol WW, Myers TG, Paull KD, Kohn KW, Weinstein JN. Use of the Kohonen self-organizing map to study the mechanisms of action of chemotherapeutic agents. J Natl Cancer Inst 1994;86:1853-9.
8. Rabow AA, Shoemaker RH, Sausville EA, Covell DG. Mining the National Cancer Institute's tumor-screening database: identification of compounds with similar cellular activities. J Med Chem 2002;45:818-40.
9. Weinstein JN, Pommier Y. Transcriptomic analysis of the NCI-60 cancer cell lines. C R Biol 2003;326:909-20.
10. Weinstein JN. Fishing expeditions. Science 1998;282:627-8.
11. Weinstein JN. 'Omic' and hypothesis-driven research in the molecular pharmacology of cancer. Curr Opin Pharmacol 2002;2:361-5.
12. Alvarez M, Paull KD, Hose C, et al. Generation of a drug resistance profile by quantitation of MDR-1/P-glycoprotein expression in the cell lines of the NCI anticancer drug screen. J Clin Invest 1995;95:2205-14.
13. Izquierdo MA, Shoemaker RH, Flens MJ, Schaffer GL, Wu L, Prather TR. Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines. Int J Cancer 1996;65:230-7.
14. Lee J-S, Paull KD, Alvarez M, et al. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol Pharmacol 1994;46:627-38.
15. Weinstein JN, Myers TG, O'Connor PM, et al. An information-intensive approach to the molecular pharmacology of cancer. Science 1997;275:343-9.
16. Myers TG, Anderson NL, Waltham M, et al. A protein expression database for the molecular pharmacology of cancer. Electrophoresis 1997; 18:647-53.
17. Ross DT, Scherf U, Eisen MB, et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000;24: 227-35.
18. Scherf U, Ross DT, Waltham M, et al. A gene expression database for the molecular pharmacology of cancer. Nat Genet 2000;24:236-44.
19. O'Connor PM, Jackman J, Bee I, et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 1997;57:4285-300.
20. Nishizuka S, Chen S-T, Gwadry FG, et al. Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. Cancer Res 2003;65:5243-50.
21. Ludwig JA, Szakacs G, Martin SE, et al. Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer. Cancer Res 2006;66:4808-15.
22. Szakacs G, Annereau JP, Lababidi S, et al. Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 2004;6:129-37.
23. Reinhold WC, Kouros-Mehr H, Kohn KW, et al. Apoptotic susceptibility of cancer cells selected for camptothecin resistance: gene expression profiling, functional analysis, and molecular interaction mapping. Cancer Res 2003;63:1000-11.
24. Kohn KW, Aladjem MI, Weinstein JN, Pommier Y. Molecular interaction maps of bioregulatory networks: a general rubric for systems biology. Mol Biol Cell 2006;17:1-13.
25. Fojo T, Farrell N, Ortuzar W, Tanimura H, Weinstein J, Myers TG. Identification of non-cross-resistant platinum compounds with novel cytotoxicity profiles using the NCI anticancer drug screen and clustered image map visualizations. Crit Rev Oncol Hematol 2005;53:25-34.
26. Ikediobi ON, Edkins S, Stevens C, et al. DNA sequence analysis of 32 known cancer genes in the NCI-60 cell lines. Mol Cancer Ther, this issue.
27. Lorenzi PL, Reinhold WC, Rudelius M, et al. Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells. Mol Cancer Ther, this issue.